Jon Congleton, Director, Chief Executive Officer, on June 30, 2026, sold 75,000 shares in Mineralys Therapeutics (MLYS) for $1,960,601. Following the Form 4 filing with the SEC, Congleton has control over a total of 614,321 common shares of the company, with 614,321 shares held directly.
SEC Filing:
c
Eugene Schneider, Executive Vice President, Chief Clinical Development Officer, on June 26, 2026, sold 26,000 shares in Ionis Pharmaceuticals (IONS) for $2,107,196. Following the Form 4 filing with the SEC, Schneider has control over a total of 77,114 common shares of the company, with 77,114 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000216/xslF345X05/edgardoc.xml
Marcelo Fischer, Chief Financial Officer, on June 26, 2026, sold 23,323 shares in IDT (IDT) for $1,329,024. Following the Form 4 filing with the SEC, Fischer has control over a total of 35,584 Class B common shares of the company, with 32,824 shares held directly and 2,760 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1005731/000119312526290844/xslF345X05/ownership.xml
Nathan Blecharczyk, 10% Owner, Director, Chief Strategy Officer, on June 26, 2026, sold 31,033 shares in Airbnb (ABNB) for $4,544,132. Following the Form 4 filing with the SEC, Blecharczyk has control over a total of 159,231 Class A common shares of the company, with 81,631 shares held directly and 77,600 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1559720/000119312526290807/xslF345X05/ownership.xml